Ensysce Biosciences (ENSC) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
7 Jan, 2026Opening remarks and agenda
The meeting was called to order virtually, with all board members introduced and the agenda outlined, including voting on five key proposals.
The virtual format was continued to ensure safety and accessibility for all stockholders.
Stockholders were informed about voting procedures and the opportunity to submit questions electronically.
Board and executive committee updates
Board composition was reviewed, with specific committee roles highlighted for each director.
Andrew Benton was acknowledged for his service as he is not standing for reelection.
Shareholder proposals
Proposal 1: Approval for full issuance of shares and exercise of warrants to comply with NASDAQ rules.
Proposal 2: Amendment to increase shares under the 2021 Omnibus Incentive Plan from 121,457 to 721,457.
Proposal 3: Election of William Chang and Lee Rauch as Class I Directors until 2028.
Proposal 4: Ratification of Baker Tilly US, LLP as independent auditor for 2025.
Proposal 5: Adjournment proposal, only to be considered if needed.
Latest events from Ensysce Biosciences
- Acquisition and new funding extend cash runway, with clinical pipeline and losses both increasing.ENSC
Q2 2026 - Innovative pain and CNS therapies advance with abuse-deterrent platforms and regulatory momentum.ENSC
Investor presentation - Shares registered for resale amid financial distress, dilution risk, and Nasdaq delisting threat.ENSC
Registration filing - Net loss of $3.6 million and clinical progress in Q1 2026 amid cash constraints.ENSC
Q1 2026 - Advancing opioid analgesics with anti-abuse and overdose protection, led by PF614 and PF614-MPAR.ENSC
Investor presentation - Urgent capital needs, dilution risk, and Nasdaq compliance challenges amid large resale registration.ENSC
Registration filing - Advanced Phase 3 programs and expanded IP, with net loss rising to $10.2M on higher R&D.ENSC
Q4 2025 - Next-gen opioid therapies with anti-abuse and overdose protection advance toward market launch.ENSC
Investor Presentation - Key votes on stock issuance, incentive plan, directors, and auditor set for January 7, 2026.ENSC
Proxy Filing